Quintrio
Home

WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES

Cardinal Health, Inc.

CAH

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Last trade $281.21
Day change -$2.64 (-0.93%)
Day range $278.46 – $284.64
Volume 769,625
Market cap $65.61B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$65.61B
Price / earnings
36.09×
Price / book
-21.69×
Price / sales
0.25×
EV / sales
0.27×
EV / EBITDA
17.77×

Profitability

Earnings per share
$7.87
Return on assets
3.05%
Return on equity
-60.1%
Dividend yield
0.74%

Liquidity and leverage

Debt / equity
-2.91×
Current ratio
0.88×
Quick ratio
0.49×
Cash ratio
0.11×

Cash flow

Price / cash flow
11.72×
Price / free cash flow
13.39×
Free cash flow
$4.9B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CAH, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$67.51B$63.67B$60.94B$65.63B$64.01B$60.16B$54.88B$55.26B
Cost of revenue$64.92B$61.11B$58.44B$63.23B$61.69B$57.96B$52.76B$53.32B
Gross profit$2.6B$2.56B$2.5B$2.4B$2.32B$2.2B$2.12B$1.94B
Selling, general and administrative$1.6B$1.63B$1.54B$1.5B$1.46B$1.48B$1.32B$1.31B
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$1.85B$1.83B$1.8B$1.69B$1.65B$1.74B$1.41B$1.39B
Operating income$749M$733M$694M$707M$670M$461M$713M$549M
Interest expense-$73M-$79M-$101M-$88M-$80M-$74M-$74M-$35M
Income before taxes$688M$554M$392M$630M$598M$384M$665M$511M
Income taxes$132M$154M$12M$159M$144M$141M$157M$110M
Net income$556M$400M$380M$471M$454M$243M$508M$401M
Net income attributable to common shareholders$554M$398M$399M$467M$450M$239M$506M$400M
EBITDA$972M$1.01B$978M$930M$923M$688M$843M$722M
Basic earnings per share$2.39$1.69$1.69$1.98$1.89$1.00$2.11$1.65
Diluted earnings per share$2.38$1.69$1.69$1.97$1.88$1.00$2.10$1.65

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Zacks.com featured highlights include NVIDIA, J.M. Smucker, Taiwan Semiconductor, Corning, Lockheed and Cardinal Health

Following NVIDIA CEO Jensen Huang's resignation that pressured tech stocks, Zacks recommends five dividend growth stocks as a steadier investment strategy amid market volatility and regulatory uncertainty. The selected companies—J.M. Smucker, Taiwan Semiconductor, Corning, Lockheed Martin, and Cardinal Health—offer consistent dividend growth, solid fundamentals, and downside protection in uncertain times.

Zacks Investment Research

5 Dividend Growth Stocks to Buy as NVDA CEO Resignation Rattles Market

Following NVIDIA CEO Jensen Huang's resignation that rattled tech stocks, investors are turning to dividend growth stocks for stability. Five stocks—J.M. Smucker, Taiwan Semiconductor, Corning, Lockheed Martin, and Cardinal Health—are highlighted as solid choices offering consistent dividend growth, reliable cash flow, and downside protection amid market volatility and regulatory uncertainty.

Zacks Investment Research

Cardinal Health (CAH) is a Top-Ranked Growth Stock: Should You Buy?

Zacks Premium offers investment tools including the Zacks Rank and Style Scores to help investors identify high-performing stocks. The Style Scores rate stocks on value, growth, and momentum characteristics, with the VGM Score combining all three. Cardinal Health (CAH) is highlighted as a #2 Buy with an A VGM Score and strong growth prospects, forecasting 14.7% year-over-year earnings growth.

Zacks Investment Research

Here's Why Cardinal Health (CAH) is a Great Momentum Stock to Buy

Cardinal Health (CAH) is highlighted as a momentum investment pick with a Zacks Rank #2 (Buy) and Momentum Style Score of B. The stock has outperformed its industry with 8.48% weekly gains and 35.15% annual returns, while recent earnings estimate revisions have moved higher, supporting its bullish outlook.

Zacks Investment Research

Zacks.com featured highlights include Stride, Ralph Lauren, Cardinal Health and Vertiv

Zacks highlights four stocks with strong interest coverage ratios, indicating solid ability to meet debt obligations: Stride (LRN) with Zacks Rank #1, Ralph Lauren (RL) with 8% sales growth expected, Cardinal Health (CAH) with 13.9% EPS growth forecast, and Vertiv Holdings (VRT) with exceptional 69.5% EPS growth projected.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.5158 per share
Declared
Nov 11, 2026
Ex-dividend
Jan 4, 2027
Pay date
Jan 15, 2027
Ex-dividendAmount / sharePay dateType
Oct 1, 2026$0.5158Oct 15, 2026recurring
Jul 1, 2026$0.5158Jul 15, 2026recurring
Apr 1, 2026$0.5107Apr 15, 2026recurring
Jan 2, 2026$0.5107Jan 15, 2026recurring
Oct 1, 2025$0.5107Oct 15, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.